Advance in Drug Delivery & Formulation Technology Series
Nanotherapeutics in the treatment of Cancer: Advances to Improve Efficacy, Bioavailability and Safety

The application of nanotechnology in the field of Medicine has rewarded all “P’s”-patients’ physicians and pharmaceutical companies. Nanotherapeutics have helped in overcoming the major limitations of the 1st generation drugs developed for the disease. Despite the major benefits achieved like protecting the normal cells from the lethality of the chemotherapy drugs, research and development is aggressively being pursued to further improve on the efficacy, specificity, targeting only the tumor site, overcoming multidrug resistance etc. The list goes on lighting hopes for better outcomes for cancer treatments. In this report we focus on the evolution of nanotherapeutics in the treatment of cancer and the advances being made in this area.

The list of approved drugs is large but pales in front of the list of drugs under development and in the clinic. Needless to state that the commercial rewards for the approved drugs are fuelling the pipeline!

A new approach for the delivery of chemotherapeutic drug is being pursued known as Nanodrug Co-Delivery System (NDCDS), in which two chemotherapeutic drugs with different physicochemical and pharmacological properties are incorporated into a single drug delivery system. The combination of chemotherapeutic drugs and other drugs target the different cellular pathway and works through different mechanisms.

In this report we discuss the promise of the novel approach, some of the drugs in the pipeline the companies, and the global market opportunity.

Author Bio

Nupur Varia

ProGrow Pharma (PGP) Partners caters the full spectrum of services to Pharma companies (Pharma/ Biotech, Generic, CRAMS, CROs, Start-ups) and its Investors (Private Equity, Fund Managers, HNI).  With decades of experience in strategic advisory, regulatory aspects, technical publications, understanding complex drugs, identifying market potential and all related services, the team is widely approached by pharmaceutical companies and experts.  Our team can support you from defining strategic programmes to providing expert guidance for tactical operations to transform your operational or market based challenges into growth aligned opportunities.

  1. Executive Summary
  2. Nanotherapeutics
    • Overview
    • Advantages of Nanotherapeutics vs. Conventional Drugs in The Treatment of Cancer
    • Types of Nanocarriers
      • Liposomes
      • Polymeric Nanoparticles
      • Polymeric Micelles
      • Quantum Dots
      • Dendrimers
      • Metal-Based Nanoparticles
      • Gold Nanoshell
      • Niosomes
      • Cubosomes
    • Nano Trojan Horse - Mechanism of Action
    • Benefits of Nanoparticles in Cancer Therapy
    • Limitations of Nanoparticles Based Anti-Cancer Therapy
  3. Approved Nanotherapeutics
  4. Nanotherapeutics in Pipeline
  5. New Frontiers- Promising Approach In Early Stage Of Development
    • Co-Delivery of Different Small Molecule Chemotherapeutic Drugs
    • Co-Delivery of Small Molecule Chemotherapeutic Drugs Plus Antibody
    • Co-Delivery of Chemotherapeutic Drugs Plus Genes
    • Co-Delivery of Small Molecule Chemotherapeutic Drug and Chemosensitizer
  6. Global Market Size of Nanotechnology-Based Drugs
  • Janseen
  • Celgene
  • Genentech/ Roche
  • Pfizer
  • Bind Therapeutics
  • Celsion
  • MagForce AG
  • Nippon Kayaku
  • Teva pharmaceuticals
  • AstraZeneca
  • Abraxis
Format Properties
SINGLE USER Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.
SITE LICENSE Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.
ENTERPRISE WIDE Electronic (PDF) The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.
Electronic (PDF)
$3,200 Buy Now

Electronic (PDF)
$4,200 Buy Now

Electronic (PDF)
$6,000 Buy Now